223445-75-8

Atagabalin (PD 0200390) is a selective GABA (gamma-aminobutyric acid) receptor agonist with antianxiety and sedative effects. Atagabalin enhances the activity of the GABA receptor by binding to the α2δ subunit of the GABA receptor, thereby increasing the GABA mediated inhibition. This enhancement results in reduced excitability of neurons, helping to reduce anxiety and improve sleep. Atagabalin can be used to study neuropsychiatric disorders, anxiety or sleep disorders[1].

ChEBI: Atagabalin is an organonitrogen compound and an organooxygen compound. It is functionally related to a gamma-amino acid.

[1] Corrigan B, et al. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage‐gated calcium channel alpha‐2‐delta subunit[J]. British journal of clinical pharmacology, 2009, 68(2): 174-180. DOI:10.1111/j.1365-2125.2009.03444.x